Agenus Inc., an immunotherapy company, engages in discovering and developing innovative treatments for patients with cancer and other diseases. Its treatments focus on providing therapeutic benefit through modulation of immune function. The company offers Retrocyte Display, a platform that screens and generates therapeutic antibody drug candidates focused on advancing checkpoint modulators using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lymphocytes. It is also developing heat shock protein vaccine, which is in Phase II studies for treating cancer and infectious diseases; and QS-21 Stimulon, a saponin-based vaccine adjuvant for use in pre-clinical and clinical stage vaccine programs that target prophylactic or therapeutic impact in a range of infectious diseases and cancer.

AGEN GROUP AGEN PAGE

0 Comments

Leave a reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

New to ALIGNMT?

Get the best experience with a subscription!

Join thousands of business leaders who recieve insightful tips on building value!

You have Successfully Subscribed!

Log in with your credentials

or    

Forgot your details?

Create Account